Cancer Therapy: Targeted Dual pH-Sensitive Lipid ECO/siRNA Self-Assembly Nanoparticles Facilitate In Vivo Cytosolic sieIF4E Delivery and Overcome Paclitaxel Resistance in Breast Cancer Therapy (Adv. Healthcare Mater. 22/2016)

Zheng-Rong Lu, Maneesh Gujrati, and co-workers design and develop simple and smart lipid ECO/siRNA self-assembly nanoparticles, which can efficiently silence the oncogene, eukaryotic translation initiation factor 4E (eIF4E), and consequently resensitize triple-negative breast cancer (TNBC) to paclitaxel on page 2882. This approach holds great promise for alleviating drug resistance in cancer therapy. Besides TNBC, the targeted multifunctional ECO/siRNA nanoparticles represent a versatile platform technology for the delivery of therapeutic siRNAs for the treatment of various other human diseases.